|
|
Article: DUSA Reports That It Will Be Reacquiring The Rights To Its Levulan PDT Dermatology Products From Schering AG, Germany.
- Article from:
- Business Wire
- Article date:
- June 7, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors
WILMINGTON, Mass.--(BUSINESS WIRE)--June 7, 2002
DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA) announced today that it has received from Schering AG, Germany, its marketing and development partner for Levulan(R) PDT in the field of dermatology, a notice of termination in accordance with the parties' marketing, development and supply agreement.
As a result, DUSA(R) will be reacquiring all rights granted under the agreement by the end of the next twelve months. DUSA will work with Schering AG, Germany, and its US affiliate, Berlex Laboratories, Inc. (Berlex) to ensure a smooth transition of all responsibilities currently being ...